Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil.

By Negrier S.   Caty A.   Lesimple T.   J-Y D.   Escudier B.   J-F R.   Viens P.   Gomez F.  

Urologic Oncology: Seminars and Original Investigations, Vol. 7, Iss. 2, 2002-03 ,pp. : 84-84

Elsevier

Access to resources Recommend Favorite

B7H4 expression and its role in interleukin2/interferon treatment of clear cell renal cell carcinoma

By              

Oncology Letters, Vol. 7, Iss. 5, 2014-01 ,pp. : 1474-1478

Spandidos Publications

Access to resources Recommend Favorite

A Randomized Phase 2 Trial of Bevacizumab with or without Daily Low-Dose Interferon Alfa-2b in Metastatic Malignant Melanoma

By Varker Kimberly   Biber Jennifer   Kefauver Cheryl   Jensen Rhonda   Lehman Amy   Young Donn   Wu Haifeng   Lesinski Gregory   Kendra Kari   Chen Helen   Walker Michael   Carson III William  

Annals of Surgical Oncology, Vol. 14, Iss. 8, 2007-08 ,pp. : 2367-2376

Springer Publishing Company

Access to resources Recommend Favorite

A phase I clinical trial of low-dose interferon-α-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma

By Amato Robert   Khan Muhammad  

Cancer Chemotherapy and Pharmacology, Vol. 61, Iss. 6, 2008-05 ,pp. : 1069-1073

Springer Publishing Company

Access to resources Recommend Favorite

Synergistic immunotherapeutic effects of Lycium barbarum polysaccharide and interferon-α2b on the murine Renca renal cell carcinoma cell line in vitro and in vivo

By                    

Molecular Medicine Reports, Vol. 12, Iss. 5, 2015-01 ,pp. : 6727-6737

Spandidos Publications

Access to resources Recommend Favorite